NexImmune, Inc. (NEXI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNexImmune, Inc. (NEXI) trades at $0.0001. NexImmune, Inc. is a clinical-stage biotechnology company focused on developing T cell immunotherapies for cancer and immune-mediated diseases. Their Artificial Immune Modulation platform drives the development of allogeneic and autologous cell therapies. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for NEXI: NEXI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
NexImmune, Inc. (NEXI) Healthcare & Pipeline Overview
NexImmune, Inc. is a clinical-stage biotechnology firm specializing in T cell immunotherapies, leveraging its Artificial Immune Modulation (AIM) platform to develop novel treatments for cancer and immune-mediated diseases. Their pipeline includes allogeneic and autologous cell therapies currently in Phase I/II clinical trials, targeting acute myeloid leukemia and multiple myeloma.
What Is the Investment Thesis for NEXI?
NexImmune operates in the high-growth biotechnology sector, focusing on innovative T cell immunotherapies. The company's AIM platform represents a novel approach to modulating the immune system, potentially offering advantages over existing cell therapy approaches. Key value drivers include the successful advancement of NEXI-001 and NEXI-002 through clinical trials, demonstrating safety and efficacy in treating AML and MM, respectively. Positive clinical data could lead to partnerships or acquisitions. A potential risk lies in the high attrition rate of clinical-stage drug development and the need for substantial capital to fund ongoing research and clinical trials. The company's small market capitalization and limited cash runway also present financial risks. The company's beta of 5.03 indicates very high volatility.
Based on FMP financials and quantitative analysis
NEXI Key Highlights
NEXI-001 is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia.
- NEXI-002 is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma.
- NEXI-003 is a candidate targeted against HPV-associated malignancies, which is in preclinical stage.
- The company's core technology is its proprietary Artificial Immune Modulation (AIM) platform.
- NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Who Are NEXI's Competitors?
NEXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals, Inc. | $15.51 | -1.27% | $53.3M | 33 5-pillar |
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NEXI's Key Strengths?
Proprietary Artificial Immune Modulation (AIM) platform.
- Pipeline of clinical-stage T cell immunotherapy candidates.
- Experienced management team with expertise in drug development.
- Focus on addressing unmet medical needs in cancer and immune-mediated diseases.
What Are NEXI's Weaknesses?
Limited financial resources and reliance on external funding.
- High attrition rate of clinical-stage drug development.
- Small market capitalization and limited trading volume.
- Dependence on the success of its lead product candidates.
What Are the Key Risks for NEXI?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and the risk of non-approval.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Limited financial resources and reliance on external funding.
- Patent challenges and intellectual property disputes.
What Are NEXI's Competitive Advantages?
- Proprietary Artificial Immune Modulation (AIM) platform.
- Patent protection for its technologies and product candidates.
- Clinical data demonstrating the safety and efficacy of its therapies.
- Expertise in T cell immunotherapy development.
What Does NEXI Do?
NexImmune, Inc., founded in 2011 and headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company dedicated to creating therapies with the potential to cure cancer and other life-threatening immune-mediated diseases. The company's core technology is its proprietary Artificial Immune Modulation (AIM) platform, which utilizes nanoparticles to modulate and direct T cell responses. This platform is designed to harness the body's own immune system to fight disease. NexImmune's lead product candidates include NEXI-001, an allogeneic cell therapy currently in Phase I/II clinical trials for acute myeloid leukemia (AML), and NEXI-002, an autologous cell therapy also in Phase I/II trials for relapsed and/or refractory multiple myeloma (MM). Additionally, NEXI-003, a preclinical candidate, targets HPV-associated malignancies. NexImmune's focus is on developing innovative immunotherapies that can provide durable responses and improve patient outcomes in areas with significant unmet medical needs. The company's research and development efforts are centered on advancing its AIM platform and expanding its pipeline of T cell-based therapies.
What Products and Services Does NEXI Offer?
- Develops T cell immunotherapies for cancer and immune-mediated diseases.
- Utilizes the Artificial Immune Modulation (AIM) platform to direct T cell responses.
- Conducts Phase I/II clinical trials for NEXI-001 in acute myeloid leukemia.
- Conducts Phase I/II clinical trials for NEXI-002 in relapsed/refractory multiple myeloma.
- Develops NEXI-003, a preclinical candidate targeting HPV-associated malignancies.
- Researches and develops novel immunotherapies to improve patient outcomes.
How Does NEXI Make Money?
- Develops and patents novel T cell immunotherapy technologies.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approval for its therapies from agencies like the FDA.
- Potentially commercializes its therapies directly or through partnerships with larger pharmaceutical companies.
What Industry Does NEXI Operate In?
NexImmune operates within the competitive biotechnology industry, which is characterized by rapid innovation and high investment in research and development. The market for cancer immunotherapies is experiencing significant growth, driven by the increasing prevalence of cancer and the demand for more effective and less toxic treatments. Key trends include the development of personalized therapies, the use of combination therapies, and the exploration of new immune targets. NexImmune's AIM platform positions it to potentially compete with established players in the cell therapy space, such as Gilead (through its acquisition of Kite Pharma) and Novartis, as well as other emerging biotechnology companies focused on immunotherapy.
Who Are NEXI's Key Customers?
- Patients with acute myeloid leukemia (AML).
- Patients with relapsed and/or refractory multiple myeloma (MM).
- Potentially, patients with HPV-associated malignancies in the future.
- Healthcare providers who treat these patient populations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
NexImmune, Inc. operates in the Healthcare sector. It is headquartered in Gaithersburg, US. NEXI has traded publicly since 2021.
Forward Outlook
Wall Street analysts project NexImmune, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.01.
Earnings Track Record
NexImmune, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 20.2% above estimates on average.
Financial Health
NexImmune, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
12 transactions · 1 purchases, 2 sales, 9 other transactions · 9 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
NEXI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NEXI Latest News
-
81 Biggest Movers From Yesterday
benzinga · May 5, 2022
NEXI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NEXI.
Price Targets
Wall Street price target analysis for NEXI.
NEXI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NEXI; grades run from A+ (80-100) to F (below 30).
Leadership: John Trainer
CEO
John Trainer serves as the CEO of NexImmune, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions at various companies, focusing on strategic planning, business development, and commercialization of novel therapies. His expertise spans across multiple therapeutic areas, including oncology and immunology. Trainer's experience also includes fundraising and investor relations.
Track Record: Under John Trainer's leadership, NexImmune has advanced its lead product candidates, NEXI-001 and NEXI-002, through Phase I/II clinical trials. He has overseen the development of the company's AIM platform and the expansion of its pipeline. Trainer has also been instrumental in securing funding for the company's research and development efforts. The company currently has 6 employees.
NEXI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NexImmune may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Limited access to company information and financial reports.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the company's capital structure and funding sources.
- Assess the risks associated with the company's industry and operations.
- Consult with a financial advisor before making any investment decisions.
- Company has a functioning website with detailed information.
- Company has patents or intellectual property related to its technology.
- Company has published scientific papers or presented at conferences.
- Company has partnerships or collaborations with reputable organizations.
- Company has a board of directors with relevant experience.
Common Questions About NEXI (Healthcare)
What are the main risks for NEXI?
The main risks for NexImmune include the inherent uncertainties of clinical-stage drug development, such as the risk of clinical trial failures or delays.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.